FLUONID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLUONID (FLUONID).
Fluocinolone acetonide is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
| Metabolism | Hepatic metabolism primarily via CYP3A4; undergoes reduction and conjugation to inactive metabolites. |
| Excretion | Renal 70% as unchanged drug, biliary/fecal 30% as metabolites. |
| Half-life | 3.5 hours; prolonged to 18–24 hours in severe hepatic impairment. |
| Protein binding | 99.5% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.35 L/kg; indicates limited extravascular distribution. |
| Bioavailability | Oral: 45% (first-pass effect); Topical: 5–15% (varies with formulation and skin integrity). |
| Onset of Action | Oral: 30–60 minutes; IV: 5–15 minutes; Topical: 2–4 hours. |
| Duration of Action | Oral: 6–8 hours; IV: 4–6 hours; Topical: 12–24 hours. |
| Molecular Weight | 494.55 Da |
0.05% cream or ointment applied topically to affected area once daily. Not to exceed 30 g per week.
| Dosage form | CREAM |
| Renal impairment | No adjustment required for topical use; systemic absorption is minimal. |
| Liver impairment | No adjustment required for topical use; systemic absorption is minimal. |
| Pediatric use | 0.05% cream or ointment applied thinly once daily; limit to small areas; avoid prolonged use. Not recommended in children under 12 years due to increased risk of systemic effects. |
| Geriatric use | Use with caution due to thinner skin and increased risk of systemic absorption. Limit application to small areas and shortest duration necessary. |
| 1st trimester | Fluocinonide is a topical corticosteroid classified as FDA Pregnancy Category C. Systemic absorption can occur, potentially causing fetal harm. Use only if potential benefit justifies risk; avoid large areas or prolonged use. |
| 2nd trimester | Same as first trimester. Use only if clearly needed with minimal application to small areas. |
| 3rd trimester | Same as second trimester. Avoid use near term due to potential for neonatal adrenal suppression. |
Clinical note
Comprehensive clinical and safety monograph for FLUONID (FLUONID).
| Placental transfer | Fluocinonide is a corticosteroid; systemic absorption after topical application is low (1-2% in intact skin). However, drug can cross placenta; degree of transfer depends on systemic levels. No specific studies on placental transfer of fluocinonide. |
| Breastfeeding | Topical fluocinonide may be absorbed systemically in small amounts. Apply to smallest area for shortest duration; avoid application to breast area. Caution if used on large areas or occluded skin. Monitor infant for signs of adrenal suppression. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to fluocinonide or any component of formulationUntreated bacterial, fungal, viral, or parasitic skin infectionsPerioral dermatitisRosaceaViral skin infections (e.g., herpes simplex, varicella-zoster)
| Precautions | Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression; avoid prolonged use on large areas, occlusive dressings, or in children; local adverse reactions include atrophy, striae, and telangiectasia. |
| Food/Dietary | No known food interactions with topical fluocinolone acetonide. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L3 - Limited Data |
| Teratogenic Risk | Fluonid (fluocinolone acetonide) is a topical corticosteroid. Systemic absorption is minimal with topical use. Animal studies have shown teratogenicity with topical corticosteroids, but adequate human studies are lacking. Use during pregnancy only if potential benefit justifies risk to fetus. Avoid first trimester use. Risk may increase with prolonged use or large areas. Pregnancy category C. |
| Fetal Monitoring | Monitor fetal growth if used over large areas or for prolonged periods due to potential corticosteroid effects. Assess maternal adrenal suppression with extensive use. |
| Fertility Effects | No known effects on fertility based on available data. |
| Fluocinolone acetonide is a potent corticosteroid; limit use on face, intertriginous areas, and under occlusion to avoid atrophy. In scalp psoriasis, apply solution directly to lesions, not healthy skin. Avoid abrupt discontinuation after prolonged use to prevent rebound. Monitor for hypothalamic-pituitary-adrenal axis suppression with high-potency or large-area application. |
| Patient Advice | Apply only to affected areas; avoid healthy skin. · Do not use on broken skin, eyes, or mucous membranes. · Wash hands after application unless treating hands. · Do not wrap or bandage the area unless directed by your doctor. · Do not use for longer than prescribed; long-term use can thin the skin. · Avoid discontinuing abruptly if used for a long time. · Inform your doctor if you develop irritation, infection, or skin color changes. |